Personalized BCG treatment for high-risk bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a personalized approach to using BCG immunotherapy for high-risk non-muscle-invasive bladder cancer. It aims to improve treatment response by tailoring the therapy based on your immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with high-risk bladder cancer that has not spread into the muscle layer.
- You have not received BCG treatment before.
- You must be older than 65 years.
- You should not have a weakened immune system (e.g., from steroids, organ transplant, or other conditions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This trial offers early access to a new form of the BCG vaccine (a treatment that helps your immune system fight bladder cancer) for people with non-muscle invasive bladder cancer. It may be an option if the standard vaccine is not available or has not worked for you.
This trial tests a new form of intravesical (given directly into the bladder) treatment called rMBCG for people with non-muscle invasive bladder cancer who have not had BCG therapy before. It may be an option for those with certain types of early bladder cancer, including carcinoma in situ (CIS) or papillary tumors after removal surgery.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This trial tests a new combination treatment (SHR-1501 plus BCG) compared to standard chemotherapy for people with bladder cancer that hasn't responded to BCG. The goal is to see if this combination works better at controlling the cancer.
This trial tests giving BCG immunotherapy at home instead of in the clinic, to reduce the burden of travel and hospital visits. It may help patients with non-muscle invasive bladder cancer who need BCG treatment after surgery.
Hear when a new NMIBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.